Title X Grantees and Clinics Affected by the Trump Administration’s Funding Freeze
This data note looks at the Title X grantees and clinics affected by the Trump Administration’s recent funding freeze.
Read More
FDA Nod for J&J Autoimmune Drug is First of Potentially Many for the Projected Blockbuster Product
Johnson & Johnson’s Imaavy is now FDA-approved for treating generalized myasthenia gravis, introducing competition to Argenx and UCB drugs that treat this rare neuromuscular disorder. J&J is also developing its new drug for other diseases and projects it could reach $5 billion in peak sales across multiple rare and prevalent conditions. The post FDA Nod…
Debunked Episode 28: A Little More Transparency, A Little More Action
Debunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed some of the takeaways from UnitedHealth Group’s press event, transparency, and pharma company Lilly’s efforts to hold hospitals accountable in 340B drug discount program. The post Debunked Episode 28: A Little More Transparency, A Little More Action appeared first on MedCity News.
From Paper Charts to AI Scribes: The EHR Revolution
AI solutions baked into the EHR experience could radically transform the clinical effectiveness of physicians by leveraging the richness of the longitudinal patient record, while also creating efficiencies that give them back more time to care and create more revenue. The post From Paper Charts to AI Scribes: The EHR Revolution appeared first on MedCity…
American Medicine’s Meagerness Paradox
By MARC-DAVID MUNK In our palliative medicine clinic in the working suburbs of Boston, my colleagues and I tend to some of the sickest patients in the city. Through the window, I can see the afflicted pull up to our squat building in family sedans, wheelchair vans, and subsidized municipal ride cars. Few drive themselves:…
My Mold Illness Nearly Broke Me — Let’s Ensure Others Get the Care They Deserve
Symptoms often get labeled as anxiety, chronic fatigue, early neurodegeneration, IBS, or fibromyalgia. How to prevent the root cause — mold exposure — from going unrecognized. The post My Mold Illness Nearly Broke Me — Let’s Ensure Others Get the Care They Deserve appeared first on MedCity News.
Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline
Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs. The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022. The post Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline appeared first on MedCity News.
Rock Health: Digital Health Funding Drops in 2024, Investors Shift Focus to Early-Stage Startups
There was a slight decrease in 2024 digital health venture funding compared to 2023, according to a new report from Rock Health. This partially due to increasing investor interest in earlier-stage startups. The post Rock Health: Digital Health Funding Drops in 2024, Investors Shift Focus to Early-Stage Startups appeared first on MedCity News.
The Fantastic Fungi — Biohybrid Bots Are Mushrooming
By KIM BELLARD I hadn’t expected to write about a biology-related topic anytime soon after doing so last week, but, gosh darn it, then I saw a press release from Cornell about biohybrid robots – powered by mushrooms (aka fungi)! They had me at “biohybrid.” The release talks about a new paper — Sensorimotor…
Why “Cleaning” Wipes Are Not Enough: Protecting Patients and Clinicians by Keeping Lead Aprons Truly Clean
Clinical care facility leaders must ensure personal protective equipment (PPE), especially lead aprons, are not just superficially clean, but clinically safe for patients and clinicians alike. The post Why “Cleaning” Wipes Are Not Enough: Protecting Patients and Clinicians by Keeping Lead Aprons Truly Clean appeared first on MedCity News.